Wednesday, September 23, 2026. 12 PM-1 PM ET
Roundtable presenters Dr. David Sacks MB, ChB, FRCPath, Chairman, Steering Committee National Glycohemoglobin Standardization Program (NGSP), and Priya Sivaraman, PhD, Senior Technical Product Manager, Tosoh Bioscience
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, September 24, 2026 11 AM-12 PM CT
This session explores the evolving role of RAS in precision oncology, from the biology of RAS mutations to the expanding landscape of targeted therapies. Through expert presentations, real-world case discussions, and interactive audience polling, participants will examine best practices for RAS biomarker testing across solid tumors, including lung, colorectal, and pancreatic cancers. The session will highlight practical considerations for tissue and liquid biopsy, strategies to address testing gaps, and the importance of multidisciplinary collaboration to ensure timely identification of patients who may benefit from RAS-targeted therapies.
Webinar presenters David Braxton, MD, Chief of Molecular Pathology Services, Hoag Family Cancer Institute & Hoag Memorial Hospital Presbyterian, and Carlos Becerra, MD, Research Director for Medical Oncology, Margaret Given Larkin Endowed Chair for Developmental Cancer Therapeutics, Hoag Memorial Hospital Presbyterian
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, September 30, 2026. 1 PM-1:30 PM ET
Roundtable presenters John Longshore, PhD, Head of Scientific Affairs, Global Oncology Diagnostics, AstraZeneca, and Flora Berisha, MS, Executive Director, Global Head of Diagnostic Partnering and Development, Johnson & Johnson Innovative Medicine, and Mark D. Ewalt, MD, Associate Medical Director for Laboratory Operations, Diagnostic Molecular Pathology, Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, and Isabel Preeshagul, DO, MBS, Thoracic Medical Oncologist, Memorial Sloan Kettering Cancer Center
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, October 1, 2026 1 PM-2 PM ET
This presentation will explore the value of in-house CGP, offer insights into the benefits and drawbacks of incorporation, and provide information about important practical factors when considering in-house implementation of CGP.
Webinar presenter Allison M. Cushman-Vokoun, MD, PhD, FCAP, Medical Director, Molecular Diagnostics and Personalized Medicine Laboratory, Director, Division of Diagnostic Molecular Pathology and Human Genetics, Henry F. Krous Professor of Pathology, University of Nebraska Medical Center
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, October 20, 2026 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
February 2014—Meridian Life Science offers several products suitable for the development of an ELISA detection assay for Ebola. The new Ebola reagents are C01762M MAb to Ebola virus, C86037M MAb to Ebola virus, C86180M MAb to Ebola virus, R01577 Ebola Zaire Nucleoprotein (E. coli) recombinant, and R01578 Ebola Sudan Nucleoprotein (E. coli) recombinant.
February 2014—EKF Diagnostics has entered a multiyear collaborative relationship with Joslin Diabetes Center in support of the ongoing clinical and commercial translation of tumor necrosis factor receptor 1 and 2 biomarkers. EKF will access certain clinical and research expertise at Joslin under the center’s corporate liaison program to further develop its TNFR biomarker test.
February 2014—Primera Technology’s robotic-based, auto-loading version of the Signature Cassette Printer, model SCP-R, is now available. Signature Cassette Printer is designed for use in pathology and histology labs to print high-resolution text, graphics, and barcodes on tissue cassettes. It uses thermal transfer ink ribbons instead of solvent ink-jet or laser ablation.
February 2014—Crescendo Bioscience, a wholly owned subsidiary of Myriad Genetics, presented data that showed Vectra DA is a better predictor of radiographic progression over two years than other tests used to assess risk of joint damage in rheumatoid arthritis.
February 2014—The Clinical and Laboratory Standards Institute has released Nongynecological Cytology Specimens: Preexamination, Examination, and Postexamination Processes; Approved Guideline—Second Edition (GP23-A2). This document provides recommendations for cytology laboratories to use in developing preexamination, examination, and postexamination processes and procedures for nongynecological cytology specimens to ensure suitable specimens for diagnosis of cancer, infectious diseases, and other inflammatory conditions. CLSI, 610-688-0100
February 2014—BioTek Instruments introduced the Cytation 5 Cell Imaging Multi-Mode Reader. The cell imager combines automated digital widefield microscopy with conventional multimode microplate detection.
February 2014—AgileBio released an add-on for LabCollector called SNP Manager, which is dedicated to the treatment of single nucleotide polymorphism genotyping workflows. Users can generate picking lists and instructions files for tube pickers (Tube Sorter and Floyd 2D) and genotyping process (Fluidigm EP1) machines.
February 2014—The FDA has cleared Randox’s Acusera Liquid Assayed Chemistry Premium Plus, a multianalyte control containing 100 commonly used analytes, for use in U.S. laboratories. Randox believes the “super control” will revolutionize quality control in laboratories, saving time and money while ensuring accurate results and patient diagnosis.
February 2014—BioCision announced the availability of the ThawStar automated sample thawing system, designed to standardize the “last mile” in the cryopreservation process. Using the patent-pending Star sensing technology, the ThawStar system tailors the thaw cycle to the specific characteristics of each frozen sample.
February 2014—Beckman Coulter Diagnostics and Seegene announced a molecular diagnostic assay supply agreement. Under the agreement, Seegene will begin manufacturing reagents designed exclusively for Beckman Coulter’s Veris MDx System, a sample-to-answer molecular diagnostics instrument.
